This enzyme family is critical for ALL outcomes and treatment response; for instance, NT5C2 mutations drive chemotherapy resistance in early relapse ALL by enhancing nucleotidase activity [34]. This evidence concerns the gene NT5C2 and acute lymphoblastic leukemia.